Drug price history · CMS NADAC read 11 November 2026

What have pharmacies paid for Capecitabine since 2013?

What pharmacies pay, not what you pay. Capecitabine has 2 products in the CMS NADAC survey, 2 products with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged. Capecitabine 500 MG Tablet: $27.41 per unit at the 2014 survey and $0.454 at 2026 (−98%).
Not medical or financial advice. This page reports what pharmacies pay to acquire a drug, from the CMS NADAC survey. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.
Capecitabine2 products in NADAC
2products with a price history
  1. Capecitabine has 2 products in the CMS NADAC survey, 2 products with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged.
  2. Between each product's first and latest year-end survey, 1 product costs pharmacies less and none costs more, by more than 5 percent, per unit as CMS states it.
  3. 1 of the changes rest on fewer than 3 priced NDCs at one end and are marked thin: a median over one or two NDCs reflects which NDCs were priced as much as a price movement.
  4. This is a per-unit acquisition cost, not a retail price, a copay or an insurer's price, and it says nothing about why a price moved.

Capecitabine 500 MG Tablet

Generic

$27.41 per unit at the 2014 year-end survey (4 NDCs) and $0.454 at the 2026 survey (17 NDCs): −98%.

$0$27.412014: median $27.41 per unit, 4 NDCs priced2015: median $23.69 per unit, 5 NDCs priced2016: median $17.04 per unit, 9 NDCs priced2017: median $10.82 per unit, 11 NDCs priced2018: median $4.30 per unit, 14 NDCs priced2019: median $3.69 per unit, 17 NDCs priced2020: median $0.586 per unit, 19 NDCs priced2021: median $0.620 per unit, 21 NDCs priced2022: median $0.559 per unit, 20 NDCs priced2023: median $0.548 per unit, 18 NDCs priced2024: median $0.467 per unit, 15 NDCs priced2025: median $0.531 per unit, 18 NDCs priced2026: median $0.454 per unit, 17 NDCs priced2014201620182020202220242026
year-end median across the NDCs pricedlowest to highest NDC
Year-end surveyMedian per unitLowest to highestNDCs priced
2014 (2014-12-31)$27.414
2015 (2015-12-30)$23.695
2016 (2016-12-28)$17.049
2017 (2017-12-27)$10.8211
2018 (2018-12-26)$4.3014
2019 (2019-12-25)$3.6917
2020 (2020-12-30)$0.58619
2021 (2021-12-29)$0.62021
2022 (2022-12-28)$0.55920
2023 (2023-12-27)$0.54818
2024 (2024-12-25)$0.46715
2025 (2025-12-31)$0.53118
2026 (2026-11-11)$0.45417

Capecitabine 150 MG Tablet

Generic

$8.27 per unit at the 2014 year-end survey (2 NDCs) and $0.362 at the 2026 survey (11 NDCs): −96%, a thin comparison.

$0$8.272014: median $8.27 per unit, 2 NDCs priced2015: median $7.24 per unit, 3 NDCs priced2024: median $0.257 per unit, 13 NDCs priced2025: median $0.396 per unit, 15 NDCs priced2026: median $0.362 per unit, 11 NDCs priced20142015202420252026
year-end median across the NDCs pricedlowest to highest NDC
Year-end surveyMedian per unitLowest to highestNDCs priced
2014 (2014-12-31)$8.272
2015 (2015-12-30)$7.243
2024 (2024-12-25)$0.25713
2025 (2025-12-31)$0.39615
2026 (2026-11-11)$0.36211

CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.

Where does Capecitabine sit on the generic price cliff?

Capecitabine 500 MG Tablet: the first generic approval in its Orange Book group is dated 2013. Its year-end acquisition cost in 2026 is 2% of its first observed year-end price (2014). The median matched product, 13 years after its first generic approval, is at 19% (the middle half runs from 14% to 39%), so this product is below that middle half.

0%25%50%75%100%0 years after the first generic approval: median 100%, middle half 100% to 100%, 79 products1 years after the first generic approval: median 95%, middle half 71% to 100%, 118 products2 years after the first generic approval: median 80%, middle half 49% to 99%, 135 products3 years after the first generic approval: median 64%, middle half 36% to 90%, 142 products4 years after the first generic approval: median 55%, middle half 25% to 84%, 154 products5 years after the first generic approval: median 46%, middle half 16% to 80%, 154 products6 years after the first generic approval: median 45%, middle half 16% to 87%, 154 products7 years after the first generic approval: median 40%, middle half 14% to 71%, 153 products8 years after the first generic approval: median 32%, middle half 8% to 65%, 131 products9 years after the first generic approval: median 28%, middle half 7% to 67%, 109 products10 years after the first generic approval: median 22%, middle half 5% to 53%, 90 products11 years after the first generic approval: median 21%, middle half 5% to 51%, 79 products12 years after the first generic approval: median 16%, middle half 6% to 34%, 48 products13 years after the first generic approval: median 19%, middle half 14% to 39%, 23 productsCapecitabine 500 MG Tablet, 1 years after the first generic approval: 100% of its first observed price, 4 NDCs pricedCapecitabine 500 MG Tablet, 2 years after the first generic approval: 86% of its first observed price, 5 NDCs pricedCapecitabine 500 MG Tablet, 3 years after the first generic approval: 62% of its first observed price, 9 NDCs pricedCapecitabine 500 MG Tablet, 4 years after the first generic approval: 39% of its first observed price, 11 NDCs pricedCapecitabine 500 MG Tablet, 5 years after the first generic approval: 16% of its first observed price, 14 NDCs pricedCapecitabine 500 MG Tablet, 6 years after the first generic approval: 13% of its first observed price, 17 NDCs pricedCapecitabine 500 MG Tablet, 7 years after the first generic approval: 2% of its first observed price, 19 NDCs pricedCapecitabine 500 MG Tablet, 8 years after the first generic approval: 2% of its first observed price, 21 NDCs pricedCapecitabine 500 MG Tablet, 9 years after the first generic approval: 2% of its first observed price, 20 NDCs pricedCapecitabine 500 MG Tablet, 10 years after the first generic approval: 2% of its first observed price, 18 NDCs pricedCapecitabine 500 MG Tablet, 11 years after the first generic approval: 2% of its first observed price, 15 NDCs pricedCapecitabine 500 MG Tablet, 12 years after the first generic approval: 2% of its first observed price, 18 NDCs pricedCapecitabine 500 MG Tablet, 13 years after the first generic approval: 2% of its first observed price, 17 NDCs priced024681012years since the first generic approval
median of 200 matched productsmiddle halfeach productCapecitabine 500 MG Tablet

This is a pattern in matched products. It does not say the first generic caused the fall, and it does not say this product's price will follow the median. See it with other drugs.

Where can you go from this record?

Open it in the check to search another drug, or see the CMS pharmacy pricing page for what NADAC measures. To check whether a drug is in shortage, see the FDA drug shortages page.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page, year-end surveys 2013 to 2026 (latest 11 November 2026).